Autres langues Akeso, Inc.

Actions

9926

KYG0146B1032

Recherche biotechnologique et médicale

Marché Fermé - Hong Kong S.E. Autres places de cotation 10:08:03 08/05/2026			Varia. 5j.	Varia. 1 janv.
134,00 ^HKD	-2,83%		-1,33%	+18,58%

28/04	Biodlink International Company Limited annonce des remaniements au sein de son conseil d'administration et de ses comités, effectifs au 29 avril 2026	CI
28/04	Akeso, Inc. obtient plusieurs mises à jour et revalorisations majeures pour l'ivonescimab dans les directives 2026 de la CSCO sur le CBNPC	CI

Autres langues

28/04	Biodlink International Company Limited Announces Board and Board Committee Changes, Effective from 29 April 2026
28/04	Ivonescimab Receives Major Recommendations Across Multiple Therapies in the 2026 CSCO NSCLC Guideline
28/04	Akeso, Inc. Secures Multiple Authoritative Updates And Upgrades For Ivonescimab In The 2026 CSCO NSCLC Guideline
21/04	Akeso, Inc. Presents Positive Phase II Results For Cadonilimab Combination In Advanced Pancreatic Cancer
21/04	Cadonilimab Combination Demonstrates Promising Survival Benefit in Locally Advanced Pancreatic Cancer: Phase II COMPASSION-26 Data Presented at AACR 2026
07/04	Akeso Presents Updated Data on Cadonilimab Combination Therapy in PD-(L)1 Inhibitor-Resistant Advanced NSCLC at ELCC 2026
07/04	Akeso Presents Updated Data on Cadonilimab Combination Therapy in PD-(L)1 Inhibitor-Resistant Advanced NSCLC at ELCC 2026
31/03	Akeso, Inc. Announces the Results of Health-Related Quality of Life Data from the HARMONi-2 Study At the 2026 European Lung Cancer Congress
31/03	Ivonescimab Shows Quality of Life Benefits in Chemotherapy-Free First-Line NSCLC: Health-Related Quality of Life Data from the HARMONi-2 Study Presented at ELCC 2026
27/03	Summit Therapeutics Inc. Announces Multiple Ivonescimab Data Sets from Phase III Studies in Advanced Nsclc Patient Populations to Be Featured At ELCC 2026
27/03	Akeso Widens Loss in 2025; Shares Climb 3%
27/03	Akeso Reports Full-Year 2025 Financial Results
26/03	Akeso, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
26/03	Akeso FY revenue RMB 3,056.3 million
25/03	Akeso Advances 'IO 2.0 + ADC 2.0' Strategy with Phase II Initiation of Novel ADCs Combined with Ivonescimab and Cadonilimab
25/03	Akeso Inc Announces Phase II Initiation Of Novel ADCs Combined With Ivonescimab And Cadonilimab
25/03	Akeso Advances "IO 2.0 + ADC 2.0" Strategy with Phase II Initiation of Novel ADCs Combined with Ivonescimab and Cadonilimab
16/03	Akeso Announces Trispecific Antibody AK150 Enters Clinical Trials
16/03	Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance
05/03	INOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma
05/03	Akeso, Inc. Presents Long-Term Phase II Results For Cadonilimab In Recurrent Or Metastatic Cervical Cancer
05/03	Cadonilimab Achieves 100% 24-Month OS in Complete Responders in R/M Cervical Cancer Based on Long-Term Phase II Results
04/03	INOVIO and Akeso Enter Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma
04/03	Akeso and Inovio announce clinical collaboration to advance novel combination therapy for glioblastoma (gbm)
04/03	Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)